Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma

被引:3
|
作者
Cui, Yong [1 ]
Li, Zhong-Wu [2 ]
Li, Xiao-Ting [1 ]
Gao, Shun-Yu [1 ]
Li, Ying [1 ]
Li, Jie [3 ]
Zhu, Hui-Ci [1 ]
Tang, Lei [1 ]
Cao, Kun [1 ]
Sun, Ying-Shi [1 ]
机构
[1] Peking Univ, Minist Educ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Dept Radiol, Beijing 100142, Peoples R China
[2] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Pathol,Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[3] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Re,Minist Educ, Beijing 100142, Peoples R China
关键词
gastroenteropancreas; neuroendocrine tumors; adenocarcinomas; computed tomography; differentiation; LYMPH-NODE METASTASIS; DIFFERENTIATION; GUIDELINES; MIDGUT; CANCER;
D O I
10.18632/oncotarget.22554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study proposed to evaluate the feasibility of dynamic enhanced CT in differentiation of liver metastases of gastroenteropancreatic well-differentiated neuroendocrine tumors (GEP NETs) from GEP adenocarcinomas based on their characteristic features. CT images of 23 well-differentiated (G1 or G2) GEP NETs and 23 GEP adenocarcinomas patients with liver metastases were retrospectively reviewed. The distribution type, shape, intra-tumoral neovascularity, enhancement on hepatic artery phase, dynamic enhancement pattern and lymphadenopathy were subjective analyzed. Meanwhile, the size, number, CT value of tumor and adjacent normal liver parenchyma were measured and the metastasis-to-liver ratios were calculated objectively. Compared with GEP adenocarcinomas, the liver metastases of GEP NETs more frequently demonstrated a hyper enhancement on hepatic artery phase, washout dynamic enhancement pattern, absence of lymphadenopathy and higher metastasis-to-liver ratios on both hepatic artery phase and portal venous phase (P=0.017, P<0.001, P=0.038, P<0.001 and P=0.008, respectively). Logistic regression analysis showed that the dynamic enhancement pattern (P=0.012), and the metastasis-to-liver ratios on hepatic artery phase (P=0.009) were independent CT predictors for liver metastases of GEP NETs. The sensitivity and specificity of combing the two predictors in differentiation of liver metastases of GEP adenocarcinomas from GEP NET were 82.6% (19 of 23) and 91.3% (21 of 23), respectively. CT features are helpful in differentiating liver metastases of well-differentiated GEP NETs from that of GEP adenocarcinomas.
引用
收藏
页码:108146 / 108155
页数:10
相关论文
共 50 条
  • [31] The Landmark Series: Neuroendocrine Tumor Liver Metastases
    Gangi, Alexandra
    Howe, James R.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (09) : 3270 - 3280
  • [32] Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
    de Mestier, Louis
    Resche-Rigon, Matthieu
    Dromain, Clarisse
    Lamarca, Angela
    La Salvia, Anna
    de Baker, Lesley
    Fehrenbach, Uli
    Pusceddu, Sara
    Colao, Annamaria
    Borbath, Ivan
    de Haas, Robbert
    Rinzivillo, Maria
    Zerbi, Alessandro
    Funicelli, Luigi
    de Herder, Wouter W.
    Selberherr, Andreas
    Wagner, Anna Dorothea
    Manoharan, Prakash
    De Cima, Andrea
    Lybaert, Willem
    Jann, Henning
    Prinzi, Natalie
    Faggiano, Antongiulio
    Annet, Laurence
    Walenkamp, Annemiek
    Panzuto, Francesco
    Pedicini, Vittorio
    Pitoni, Maria Giovanna
    Siebenhuener, Alexander
    Mayerhoefer, Marius E.
    Ruszniewski, Philippe
    Vullierme, Marie-Pierre
    JOURNAL OF NEUROENDOCRINOLOGY, 2023,
  • [33] The Landmark Series: Neuroendocrine Tumor Liver Metastases
    Alexandra Gangi
    James R. Howe
    Annals of Surgical Oncology, 2020, 27 : 3270 - 3280
  • [34] Radioembolization in the Treatment of Neuroendocrine Tumor Metastases to the Liver
    Vyleta, Martin
    Coldwell, Douglas
    INTERNATIONAL JOURNAL OF HEPATOLOGY, 2011, 2011
  • [35] Surgical Management of Neuroendocrine Tumor Liver Metastases
    Tran, Catherine G.
    Sherman, Scott K.
    Chandrasekharan, Chandrikha
    Howe, James R.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 30 (01) : 39 - 55
  • [36] IDENTIFICATION OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR WITH HIGH LIVER TUMOR BURDEN BASED ON CLINICOPATHOLOGICAL FEATURES
    Jumai, Nuerailaguli
    Chen, Luohai
    He, Qiao
    Liu, Man
    Wen, Wenli
    Lin, Yuan
    Luo, Yanji
    Wang, Yu
    Chen, Minhu
    Zeng, Zhirong
    Zhang, Xiangsong
    Zhang, Ning
    GASTROENTEROLOGY, 2024, 166 (05) : S1340 - S1341
  • [37] Identification of gastroenteropancreatic neuroendocrine tumor with high liver tumor burden based on clinicopathological features
    Jumai, N.
    Chen, L.
    He, Q.
    Liu, M.
    Wen, W.
    Lin, Y.
    Luo, Y.
    Wang, Y.
    Chen, M. H.
    Zeng, Z.
    Zhang, X.
    Zhang, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 158 - 158
  • [38] Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma
    Leboulleux, S
    Baudin, E
    Young, J
    Caillou, B
    Lazar, V
    Pellegriti, G
    Ducreux, M
    Schaison, G
    Schlumberger, M
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (03) : 187 - 191
  • [39] CONTEMPORARY PATTERNS AND OUTCOMES OF LIVER-DIRECTED THERAPY IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS AND LIVER METASTASES
    Strong, Erin A.
    Gracz, Maciej
    Livingston, Austin
    Barnes, Chad
    Clarke, Callisia N.
    GASTROENTEROLOGY, 2020, 158 (06) : S1563 - S1564
  • [40] Circulating Tumor DNA (Ct DNA) as a Biomarker in High-Grade Gastroenteropancreatic Neuroendocrine Tumor
    Mukherjee, S.
    Choi, M.
    Ramirez, R.
    Attwood, K.
    Iyer, R.
    PANCREAS, 2021, 50 (03) : 466 - 467